A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
BUSINESS
Daiichi Sankyo’s Revenue Up 16.9% in April-December on Buoyant Mainstays
Daiichi Sankyo said on January 31 that its April-December sales grew 16.9% year on year, bolstered by the growth of its mainstay products such as the anticoagulant Lixiana (edoxaban) and the cancer med Enhertu (trastuzumab deruxtecan). The depreciating yen also…
To read the full story
Related Article
- Daiichi Sankyo Ups Outlook on Earnings Growth Driven by Enhertu
November 1, 2024
- Daiichi Sankyo’s Q1 Sales Grow 24% as Mainstays Fare Well
August 1, 2024
- Daiichi Sankyo Ups FY2025 Sales Goal to 2.1 Trillion Yen on Bullish Cancer Biz
April 26, 2024
- Daiichi Sankyo Ups Full-Year Outlook on Growth of Flu, COVID Products
February 1, 2024
- Daiichi Sankyo’s H1 Sales Jump 19.5% on Robust Global Products
November 1, 2023
- Daiichi Sankyo Enjoys Rosy Q1 Earnings on Strong Mainstays
August 1, 2023
- Daiichi Sankyo on Path to Net 2 Trillion Yen in Sales by FY2025 on Robust Core Products
April 28, 2023
- Daiichi Sankyo Nets Double-Digit Rise in H1 Sales as Major Products Fare Well
November 1, 2022
- Daiichi Sankyo Q1 Sales Rise 6.2% on Robust Enhertu Performance, Weaker Yen
August 1, 2022
- Daiichi Sankyo Breaks 1 Trillion Mark in FY2021 Sales on Bullish Enhertu, Lixiana
April 28, 2022
- Daiichi Sankyo’s Revenue Rises 9.8% in April-December on Upbeat Mainstays
February 1, 2022
- Daiichi Sankyo’s 1st Half Operating Profit Jumps 44.9% Thanks to Lixiana, Enhertu
November 1, 2021
- Daiichi Sankyo’s Q1 Sales Surge on Upbeat Global Brands
August 2, 2021
- Daiichi Sankyo Sales Slip in FY2020 as Price Cuts, Deal Termination Weigh
April 28, 2021
- Daiichi Sankyo’s Revenue Down 2.4% in April-December as Mainstays Flounder at Home
February 1, 2021
- Daiichi Sankyo’s 6-Month Operating Profit Falls 32% on Higher SGA Costs for Enhertu, ADC R&D Spending
November 2, 2020
- Daiichi Sankyo Sales Skid 4.9% on Coronavirus, Price Cuts; Enhertu, Edoxaban Upbeat
August 3, 2020
BUSINESS
- Meiji Pharma Sues CDP Lawmaker for Defamation over Kostaive
December 26, 2024
- ASKA In-Licenses Another Women’s Health Drug from Insud
December 26, 2024
- Sandoz’s Rituximab Biosimilar Adds Pediatric ITP Indication
December 26, 2024
- Nihon Servier Files Glioma Drug Vorasidenib in Japan
December 25, 2024
- Sumitomo’s Gemtesa Expands Label in US to OAB Patients with BPH
December 25, 2024
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…